Table 2 Description and outcomes of pregnancies fathered by male kidney transplant patients

Age, median (IQR), years

41 (36–48)

41 (36–48)

42 (37–48)

43 (37.5–49)

48 (44–52)

Age at conception, median (IQR), years

34 (30–37)

33 (21–36)

35 (31–39)

37 (34–40)

41 (40–44)

Year of first transplantation, median (IQR)

2006 (1999–2010)

2006 (1999–2010)

2006 (1996–2008)

2005 (1994–2007)

1994 (1986–2002)

Transplant to conception time in years, median (IQR)

5 (2–8)

4 (1.5–7)

7 (4–10)

8 (6–11)

16 (13–19)

 Corticosteroids

298 (74%, [69–78])

176 (72%, [66–77])

84 (73%, [64–81])

29 (83%, [66–93])

9 (100%, [66–100])

 Azathioprine

59 (15%, [11–18])

44 (18%, [13–23])

13 (11%, [6–19])

1 (3%, [0.7–15])

1 (11%, [0.3–50])

 MMF/MPA

313 (77%, [73–81])

190 (78%, [72–83])

92 (80%, [72–87])

26 (74%, [57–88])

5 (56%, [21–86])

 Tacrolimus

255 (63%, [58–68])

156 (64%, [57–70])

70 (61%, [51–70])

22 (63%, [45–79])

7 (78%, [40–97])

 Cyclosporine

152 (38%, [33–43])

94 (38%, [32–45])

43 (37%, [29–47])

13 (37%, [21–55])

2 (22%, [3–60])

 Everolimus

5 (1%, [0.5–3])

3 (1%, [0.3–4])

2 (2%, [0.2–6])

0 (0%, [0–10])

0 (0%, [0–33])

 Sirolimus

7 (2%, [1–4])

5 (2%, [0.7–5])

2 (2%, [0.2–6])

0 (0%, [0–10])

0 (0%, [0–33])

 Belatacept

6 (1%, [0.5–3])

4 (2%, [0.4–4])

1 (1%, [0.1–5])

1 (3%, [0.7–15])

0 (0%, [0–33])

 Other^b

40 (10%, [7–13])

18 (7%, [4–11])

16 (14%, [8–22])

5 (14%, [5–30])

1 (11%, [0.3–50])

Rejection episode before or during pregnancy

80 (20%, [16–24])

40 (16%, [12–22])

29 (25%, [18–34])

8 (23%, [10–40])

3 (33%, [7–70])

 Live births, including 6 twin pregnancies

349 (86%, [83–90])

222 (91%, [86–94])

94 (82%, [73–88])

26 (74%, [57–88])

7 (78%, [40–97])

 Twin pregnancy

7 (2%, [0.5–3])

5 (2%, [0.7–5])

1 (1%, [0.1–5])^c

1 (3%, [0.7–15])

0 (0%, [0–33])

 Spontaneous abortion

37 (9%, [7–12])

18 (7%, [4–11])

14 (12%, [7–20])

4 (11%, [3–27])

1 (11%, [0.3–50])

 Therapeutic abortion

12 (3%, [2–5])

6 (2%, [0.9–5])

2 (2%, [0.2–6])

3 (9%, [2–23])

1 (11%, [0.3–50])

 Still births

2 (0.5%, [0.1–1])

0 (0%, [0–0.1])

0 (0%, [0–3])

2 (6%, [1–19])

0 (0%, [0–33])

 Ongoing pregnancy

10 (2%, [1–5])

4 (2%, [0.4–4])

5 (4%, [1–10])

1 (3%, [0.7–15])

0 (0%, [0–33])

Live births, including twin pregnancies

349

222

94

26

7

 Gestational age in weeks, median (IQR)

41 (39–41)

41 (38–41)

41 (39–41)

41 (39–41)

41 (39–41)

 Pre-term delivery (< 37 weeks)

30 (9%, [6–12])

23 (10%, [7–15])

5 (5%, [2–12])

2 (8%, [1–25])

0 (0%, [0–41])

 Birthweight (Kg), median (IQR)

3.4 (3–3.7)

3.3 (3–3.7)

3.4 (3–3.8)

3.5 (3–3.6)

3.5 (3.2–3.8)

 Low birthweight (< 2.5 Kg)

20 (6%, [4–9])

16 (7%, [4–11])

3 (3%, [1–9])

1 (4%, [0.1–20])

0 (0%, [0–41])

 Sex (male)

193 (55%, [50–61])

127 (57%, [50–64])

47 (50%, [40–60])

16 (62%, [41–80])

3 (43%, [10–82])

 Intellectual disability

3 (1%, [0.2–3])

3 (1%, [0.3–4])

0 (0%, [0–4])

0 (%, [0–13])

0 (0%, [0–41])

 Congenital malformation

13 (4%, [2–6])

10 (5%, [2–8])

3 (3%, [1–9])

0 (%, [0–13])

0 (0%, [0–41])